ZY D1
Alternative Names: ZYD-1Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Zydus Cadila
- Class Antihyperglycaemics; Antihyperlipidaemics; Antirheumatics
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Obesity in India
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in India (SC)
- 30 Nov 2012 ZY D1 is still in phase I development for Obesity and Type-2 diabetes mellitus in India